Evotec SE
Business
Evotec SE provides integrated drug discovery, development and manufacturing services as an external innovation partner to pharmaceutical and biotechnology companies. It offers Discovery Services, Development & Manufacturing Services, ADME‑Tox solutions via Cyprotex, and biologics design, development and commercial manufacturing through Just – Evotec Biologics, supported by platforms such as PanOmics, iPSC disease modeling, molecular patient databases and AI/ML analytics. The business is organized into Shared R&D and Just – Evotec Biologics reporting segments. Evotec serves global partners across industry, academia, foundations and venture capital through fee‑for‑service, FTE and collaborative co‑development arrangements.
Summary from filing dated 2025-04-17
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | — |
| Net income | $-103.52M |
| Total assets | $1.71B |
| Total liabilities | — |
| Stockholders' equity | — |
| Operating cash flow | — |